Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES502 in Advanced Pancreatic Cancer and Other Solid Tumors
NCT07649928Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ES502 in pancreatic cancer (PC) and solid tumor, sponsored by Ruijin Hospital. Primary endpoints: Safety and Tolerability at 2 years and Maximum Tolerated Dose at 2 years. Started May 2026; status: recruiting.
02
Drugs
ES502
03
Conditions
pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT07649928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07649928.